KURA

In the past six months (April 2026 - October 2026), Kura Oncology's stock (KURA) trended upwards by approximately 19.68% to 20.32%. Key events included reporting $5.8 million in KOMZIFTI net product revenue in Q1 2026 and $9.1 million in Q2 2026, demonstrating robust new patient starts and broad payer access. Insider activity in August 2026 saw President and CEO Troy Edward Wilson purchase 100,000 shares of common stock. In September 2026, Kura Oncology launched Caspian Therapeutics with $50 million in financing to advance menin inhibition for diabetes, unveiling preclinical data for KO-7246 in diabetes. A tax-related stock sale by the legal chief occurred in September 2026. Analyst ratings from several research firms reiterated 'Market Outperform' or 'Buy' ratings with price targets ranging from $15 to $76, and an average 12-month target price of $25.69.